-
The cancer drug leucovorin has been in high demand since the Trump administration endorsed it as a treatment for some autistic kids. Some experts say the drug's popularity has outpaced the science.
-
New research is underway to test whether a combination of high-intensity interval training and generic medicines can slow down aging and fend off age-related diseases. Here's how it might work.
-
The Administration for a Healthy America is RFK Jr.'s plan to tackle chronic disease, addiction and other persistent problems. But so far it's not being set up like previous new agencies.
-
More than 550 people have contracted measles in Spartanburg County, S.C., in a fast-growing outbreak. Like a majority of U.S. counties, nonmedical exemptions to school vaccination are also rising.
-
Many jails and prisons around the country don't provide medication treatment for opioid use disorder. Studies show that medication makes recovery more likely and reduces the risk of overdose death.
-
More Americans are turning to ketamine for relief from depression, anxiety, even chronic pain.
-
All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their prices for 2026.
-
A hospice in Uganda asked itself: Can we do more than ease the pain of dying? Can we actually prevent deaths from cervical and breast cancer?
-
All seven of North Carolina’s recent measles cases are in Western North Carolina, including two newly confirmed infections in Buncombe County at a school with low vaccination rate.
-
North Carolina needs $5 million for the federal government to provide $125 million for the SUN Bucks program. It helps feed more than a million kids.
-
UNC Health says last year, its providers began limiting medical services around gender transition to patients who are at least 19 years of age, in response to pending federal guidelines around this issue. This exceeds state law, which prohibits gender-affirming care for those under 18.
-
A recent change puts some long-recommended childhood vaccines in a new category called "shared clinical decision-making." The ramifications of this seemingly wonky change could be far-reaching.